194 related articles for article (PubMed ID: 38361757)
21. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
Li Y; Mo H; Jia S; Wang J; Ma Y; Liu X; Tu K
Front Immunol; 2022; 13():1066773. PubMed ID: 36582227
[TBL] [Abstract][Full Text] [Related]
22. The core role of macrophages in hepatocellular carcinoma: the definition of molecular subtypes and the prognostic risk system.
Wang Q; Lin Y; Yu W; Chen X; He Q; Ye Z
Front Pharmacol; 2023; 14():1228052. PubMed ID: 37693905
[No Abstract] [Full Text] [Related]
23. Single-cell transcriptomics reveals the role of Macrophage-Naïve CD4 + T cell interaction in the immunosuppressive microenvironment of primary liver carcinoma.
Mo Z; Liu D; Chen Y; Luo J; Li W; Liu J; Yu L; Huang B; Zhang S
J Transl Med; 2022 Oct; 20(1):466. PubMed ID: 36221095
[TBL] [Abstract][Full Text] [Related]
24. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract][Full Text] [Related]
25. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract][Full Text] [Related]
26. Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data.
Yu L; Shen N; Shi Y; Shi X; Fu X; Li S; Zhu B; Yu W; Zhang Y
Front Immunol; 2022; 13():1009789. PubMed ID: 36211448
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
[TBL] [Abstract][Full Text] [Related]
28. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
29. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
[TBL] [Abstract][Full Text] [Related]
30. Fibronectin 1 derived from tumor-associated macrophages and fibroblasts promotes metastasis through the JUN pathway in hepatocellular carcinoma.
Zhang L; Zhang C; Xing Z; Lou C; Fang J; Wang Z; Li M; He H; Bai H
Int Immunopharmacol; 2022 Dec; 113(Pt A):109420. PubMed ID: 36461607
[TBL] [Abstract][Full Text] [Related]
31. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.
Zhang X; Zhuge J; Liu J; Xia Z; Wang H; Gao Q; Jiang H; Qu Y; Fan L; Ma J; Tan C; Luo W; Luo Y
Front Immunol; 2023; 14():1153423. PubMed ID: 37006285
[TBL] [Abstract][Full Text] [Related]
32. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
33. Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment.
Zhang G
Front Immunol; 2022; 13():975762. PubMed ID: 36189226
[TBL] [Abstract][Full Text] [Related]
34. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
35. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
36. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
37. Identification and immunoprofiling of key prognostic genes in the tumor microenvironment of hepatocellular carcinoma.
Wang T; Chen B; Meng T; Liu Z; Wu W
Bioengineered; 2021 Dec; 12(1):1555-1575. PubMed ID: 33955820
[TBL] [Abstract][Full Text] [Related]
38. Three molecular subtypes and a five-gene signature for hepatocellular carcinoma based on m7G-related classification.
Yue Y; Tao J; An D; Shi L
J Gene Med; 2024 Jan; 26(1):e3611. PubMed ID: 37847055
[TBL] [Abstract][Full Text] [Related]
39. An asparagine metabolism-based classification reveals the metabolic and immune heterogeneity of hepatocellular carcinoma.
Bai J; Tang R; Zhou K; Chang J; Wang H; Zhang Q; Shi J; Sun C
BMC Med Genomics; 2022 Oct; 15(1):222. PubMed ID: 36284275
[TBL] [Abstract][Full Text] [Related]
40. Single-cell histone chaperones patterns guide intercellular communication of tumor microenvironment that contribute to breast cancer metastases.
Xie J; Deng W; Deng X; Liang JY; Tang Y; Huang J; Tang H; Zou Y; Zhou H; Xie X
Cancer Cell Int; 2023 Dec; 23(1):311. PubMed ID: 38057779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
